Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Has results × Priapism × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 697 Breast Neoplasms 645 Carcinoma, Non-Small-Cell Lung 638 Neoplasm Metastasis 299 Colorectal Neoplasms 294 Prostatic Neoplasms 291 Multiple Myeloma 256 Melanoma 255 Leukemia, Myeloid, Acute 206 Ovarian Neoplasms 200 Recurrence 199 Lymphoma, Non-Hodgkin 180 Lung Neoplasms 179 Carcinoma, Renal Cell 177 Lymphoma 162 Lymphoma, Follicular 143 Pancreatic Neoplasms 141 Leukemia, Lymphocytic, Chronic, B-Cell 133 Carcinoma, Hepatocellular 128 Leukemia 117 Stomach Neoplasms 115 Lymphoma, Large B-Cell, Diffuse 108 Head and Neck Neoplasms 105 Parkinson Disease 4, Autosomal Dominant Lewy Body 102 Urinary Bladder Neoplasms 96 Carcinoma 95 Precursor Cell Lymphoblastic Leukemia-Lymphoma 88 Squamous Cell Carcinoma of Head and Neck 86 Small Cell Lung Carcinoma 86 Glioblastoma 85

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01895361 2020-01-31

SUSTAIN

Reprixys Pharmaceutical Corporation

Phase 2 Completed

198 enrolled 18 charts 1 FDA

Classical hematology

Anemia, Sickle Cell, Priapism

Data powered by HemOnc (CC BY 4.0) Colophon ⚡